NVCR News and Press, NovoCure Limited From 02/23/22

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.10 (-350.0% Y/Y) and the consensus Revenue Estimate is $134.49M (-6.6% Y/Y). Over the last 1 year, NVCR has beaten EPS estimates 25% of the tim...

So far in 2022, the stock market has been ugly, and stocks have been hammered across the board, including healthcare stocks. Is it possible to find some future winners in this bear market? Sure. When the world turns awful, healthcare is usually a bright spot. Upheaval in Ukraine means m...

The mini-crash of January has given investors the opportunity to buy some amazing healthcare companies at a discount. First we're going to take a look at Doximity (NYSE: DOCS) , a telehealth powerhouse that is almost 60% off its highs. Next up is Novocure (NASDAQ: NVCR) , a ...

Oppenheimer has upgraded shares of NovoCure (NVCR +1.6%) from perform to outperform citing the company's current valuation and growth from the release of next-generation arrays mid year. The firm has a $98 price target (~37% upside based on yesterday's close). Analyst Kevin DeGeeter wrote tha...

Shares of Novocure (NASDAQ: NVCR) have plunged more than 70% below their highs set last summer. What should investors do? In this Motley Fool Live video recorded on Jan. 19 , Motley Fool contributors Keith Speights and Brian Orelli talk about why focusing on the long-te...

Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which r...

Preliminary full year 2021 net revenues of $535 million and fourth quarter net revenues of $133 million DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated in early Q2 2022 given limited total number of events to date in fast-recruiting trial ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks have been center stage since the start of Covid-19. Biopharma companies have been striving to develop and commercialize life-saving vaccines and antiviral pills to fight the pandemic. In the past sev...

Novocure (NASDAQ: NVCR) announced today it will participate in the 40 th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analy...

Novocure (NASDAQ:NVCR) signed a purchase and sale agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire. The purchase price of the property is $9.5M. On agreement closure, Novocure will enter into a construction ...